Efficacy and safety of self-emulsifying formulation of highly purified eicosapentaenoic acid ethyl ester (MND-2119) versus highly purified eicosapentaenoic acid ethyl ester in patients with hypertriglyceridemia: Results from a 12-week randomized, double-blind, active-controlled, phase 3 study


      • MND-2119 is a self-emulsifying eicosapentaenoic acid ethyl ester.
      • MND-2119 was tested in hypertriglyceridemia patients.
      • MND-2119 2 g/day was non-inferior to Epadel 1.8 g/day in lowering TG levels.
      • MND-2119 4 g/day was superior to MND-2119 2 g/day in lowering TG levels.
      • MND-2119 appeared safe and well tolerated.



      In Japan, eicosapentaenoic acid ethyl ester (EPA-E) is administered twice-daily or three-times-daily for dyslipidemia. We have developed MND-2119, a novel self-emulsifying formulation of highly purified EPA-E, which can be administered once-daily.


      The objective of this study was to assess non-inferiority in the efficacy of MND-2119 in patients with hypertriglyceridemia compared with highly purified EPA-E.


      In this multicenter, 12-week, double-blind study, patients with high triglyceride (TG levels between ≥ 150 and < 500 mg/dL) undergoing lifestyle modification were randomized to MND-2119 2 g/day (n=145), MND-2119 4 g/day (n=145), EPA-E 1.8 g/day (n=145) or EPA-E 2.7 g/day (n=145). The primary endpoint was percentage change in TG levels from baseline to end of treatment.


      MND-2119 2, 4 g/day and EPA-E 1.8, 2.7 g/day reduced TG levels from baseline by −10.09%, −15.51%, −9.30%, and −8.80%, respectively. The TG reduction rate of MND-2119 2 g/day was non-inferior to that of EPA-E 1.8 g/day (LS mean difference: -0.42, 95%CI: -5.76 to 4.91). Moreover, the TG reduction rate of MND-2119 4 g/day was superior to that of MND-2119 2 g/day (LS mean difference: -5.74, 95%CI: -10.59 to -0.89). There were no remarkable safety differences between MND-2119 2 g/day and EPA-E 1.8 g/day and between MND-2119 4 g/day and EPA-E 2.7 g/day.


      Non-inferiority of MND-2119 2 g/day to EPA-E 1.8 g/day for efficacy, and superiority of MND-2119 4 g/day over MND-2119 2 g/day for efficacy were verified. MND-2119 was safe and well tolerated.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Clinical Lipidology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Iso H
        • Imano H
        • Yamagishi K
        • Ohira T
        • Cui R
        • Noda H
        • et al.
        Fasting and non-fasting triglycerides and risk of ischemic cardiovascular disease in Japanese men and women: The Circulatory Risk in Communities Study (CIRCS).
        Atherosclerosis. 2014 Nov 1; 237: 361-368
        • National Cholesterol Education Program (NCEP)
        Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.
        Circulation. 2002 Dec 17; 106: 3143-3421
        • Graham I
        • Atar D
        • Borch-Johnsen K
        • Boysen G
        • Burell G
        • Cifkova R
        • et al.
        European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts).
        Eur Heart J. 2007 Oct; 28: 2375-2414
        • Kinoshita M
        • Yokote K
        • Arai H
        • Iida M
        • Ishigaki Y
        • Ishibashi S
        • et al.
        Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2017.
        J Atheroscler Thromb. 2018 Sep 1; 25: 846-984
        • Saini SD
        • Schoenfeld P
        • Kaulback K
        • Dubinsky MC.
        Effect of medication dosing frequency on adherence in chronic diseases.
        Am J Manag Care. 2009 Jun 1; 15: e22-e33
        • Yokoyama M
        • Origasa H
        • Matsuzaki M
        • Matsuzawa Y
        • Saito Y
        • Ishikawa Y
        • et al.
        Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis.
        Lancet. 2007 Mar 31; 369: 1090-1098
        • Davidson MH
        • Johnson J
        • Rooney MW
        • Kyle ML
        • Kling DF.
        A novel omega-3 free fatty acid formulation has dramatically improved bioavailability during a low-fat diet compared with omega-3-acid ethyl esters: the ECLIPSE (Epanova® compared to Lovaza® in a pharmacokinetic single-dose evaluation) study.
        J Clin Lipidol. 2012 Nov; 6: 573-584
        • Ballantyne CM
        • Bays HE
        • Kastelein JJ
        • Stein E
        • Isaacsohn JL
        • Braeckman RA
        • et al.
        Efficacy and Safety of Eicosapentaenoic Acid Ethyl Ester (AMR101) Therapy in Statin-Treated Patients With Persistent High Triglycerides (from the ANCHOR Study).
        Am J Cardiol. 2012 Oct 1; 110: 984-992
        • Itakura H
        • Yokoyama M
        • Matsuzaki M
        • Saito Y
        • Origasa H
        • Ishikawa Y
        • et al.
        Relationships between Plasma Fatty Acid Composition and Coronary Artery Disease.
        J Atheroscler Thromb. 2011; 18: 99-107
        • Bays HE
        • Ballantyne CM
        • Doyle Jr, RT
        • Juliano RA
        • Philip S.
        Icosapent ethyl: Eicosapentaenoic acid concentration and triglyceride-lowering effects across clinical studies.
        Prostaglandins Other Lipid Mediat. 2016 Sep; 125: 57-64
        • Bhatt DL
        • Steg PG
        • Miller M
        • Brinton EA
        • Jacobson TA
        • Ketchum SB
        • et al.
        Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.
        N Engl J Med. 2019 Jan 3; 380: 11-22
        • Bhatt DL
        • Miller M
        • Steg PG
        • Brinton EA
        • Jacobson TA
        • Ketchum SB
        • et al.
        EPA Levels and Cardiovascular Outcomes in the Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial [Presentation Slides].
        American College of Cardiology/World Congress of Cardiology. 2020;
        • Lombardi M
        • Carbone S
        • Del Buono MG
        • Chiabrando JG
        • Vescovo GM
        • Camilli M
        • et al.
        Omega-3 fatty acids supplementation and risk of atrial fibrillation: an updated meta-analysis of randomized controlled trials.
        Eur Heart J Cardiovasc Pharmacother. 2021 Jul 23; 7: e69-e70